SOURCE: BDI Pharma, Inc.

BDI Pharma, Inc.

October 18, 2010 07:00 ET

Biotech Distributor BDI Pharma Continues Record Growth in Revenue and Job Creation Through FYQ3

COLUMBIA, SC--(Marketwire - October 18, 2010) -  BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of biotech therapies, announced that Sales Revenues for the first three (3) fiscal quarters of 2010 represented an increase of more than twenty-four percent (24%) compared with the same time period in 2009. The Specialty Biopharmaceutical class of products, specifically in the clinical area of Oncology, has grown more than six-fold over last year through the first nine (9) months of 2010. Also notable was continued growth within the Protein Biotherapeutics class, specific to the Hemophilia and Hyper-Immune product lines.

"We are excited about the growth of BDI Pharma and its new divisions," said Richard J. Gaton, Co-President of BDI Pharma. "It is rewarding to witness a strategic plan unfold from inception to implementation." Not lost on Mr. Gaton is the hard work and dedication of the BDI Pharma team. "Significant man hours have been dedicated to achieving our initiatives for 2010. As pleased as we are with the increased revenue, we are equally proud to be in a position to continue to create jobs in the current economic environment."

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, has become an industry-renowned point of reference. Proprietary programs for veterinarians --; product consignment --; flu vaccine pre-booking --; vaccine ordering --; and purchasing/reward programs -- and round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma's portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or "hyper" immune globulins, and other specialty injectables. BDI Pharma is recognized as an "ADR," or Authorized Distributor of Record, for all of the manufacturers it represents.

Contact Information

  • Contact:
    Brad Davis
    Assistant Vice President, Marketing